Cortendo banks $26.4M; Bayer homes in on life sciences;

@FierceBiotech: ICYMI yesterday: $SNY drops the ax on 100 R&D staffers in Boston reorganization. Article | Follow @FierceBiotech

@JohnCFierce: J&J's R&D group crafts 3 new platforms to guide global drug development. Story | Follow @JohnCFierce

@DamianFierce: Things @AcordaNews has: 1. An Instagram account  2. A softball team called "COHEN'S CRUSHERS." Picture | Follow @DamianFierce

> Sweden's Cortendo hauled in $26.4 million in a private placement, cash that will help fund its Phase III trial of a drug for the rare Cushing's syndrome. More

> Bayer is reshaping its business to focus on life sciences, preparing to spin off its plastics arm over the next year. News

Medical Device News

@FierceMedDev: ICYMI yesterday: Intraocular lens maker Staar Surgical gets warning letter over its manufacturing practices. Story | Follow @FierceMedDev

@VarunSaxena2: UPDATED w/results of the sale: Trovagene raises $23M in follow-on share offering for urine-based cancer diagnostic. FierceDiagnostics article | Follow @VarunSaxena2

@EmilyWFierce: Scientists unveil new biomarker for early detection of dementia through blood test. Report | Follow @EmilyWFierce

> Bayer starts reorg as it explores sale of diabetes biz. More

> Invitae's $102M IPO stands alone as three med tech IPOs remain sidelined. Story

> Sanofi backs Europe's first remote clinical trial--for a smart glucose monitor. Article

Pharma News

@FiercePharma: Embattled Zoetis beats Q4 expectations, but tempers 2015 forecasts. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: In merely one week from THIS very moment, you could be listening to me moderate this super cool webinar: … Sign up! | Follow @CarlyHFierce

> Supplies of Roche's Tamiflu drained in HK as monthlong H3N2 outbreak hits. News

> Bayer rolls up its sleeves for major reorg after plastics unit departs. Story

> Hedge funder's first assault on iffy drug patents? Acorda's MS med Ampyra. Report

Vaccines News

> Advaxis inks pact with Incyte to test cervical cancer vaccine combo. Item

> Vaxxas scores $20M to develop needle-free vaccines. Article

> Serum Institute and Cipla in early merger talks. More

> GSK nabs pipeline prospects, conjugate vaccine tech with GlycoVaxyn buyout. Story

> GSK lays off 27 vaccine researchers in Montana. Report

Pharma Manufacturing News

> Genzyme biologics plant continues to pay off for Sanofi. Report

> Hospira recalls 60 lots of pain drug. Report

> Another doctor convicted for selling foreign-made drugs. Article

> GSK resolving shortage of Nicorette Lozenges. Story

> Report: 'Carrot and stick' needed to deal with drug shortages. More

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.